Caladrius Biosciences is developing innovative products to treat cardiovascular and autoimmune diseases. We have four programs in mid to late stage development centered around two different proprietary technologies, each of which offers multiple product opportunities. Our carefully selected programs involve disease areas in which Caladrius’s management team has significant expertise, where there is a recognized significant unmet medical need and where we believe we can compete effectively. CLBS12 (a candidate for critical limb ischemia) underway in Japan. CLBS12 has received SAKIGAKE designation for expedited development and review and has been deemed eligible for consideration of early conditional approval by the Japanese regulatory authorities. CLBS14 is Caladrius’s proprietary and patent-protected formulation of CD34+ cells designed specifically to repair and regenerate cardiovascular tissue. CLBS14-CMD is being studied in the ongoing ESCaPE-CMD Phase 2 clinical trial in the USA for coronary microvascular dysfunction and CLBS14-NORDA (formerly CLBS14-RfA), a late-stage development program in the USA for no-option refractory disabling angina. CLBS03 is an autologous ex vivo polyclonal T regulatory cell ("Treg") clinical Phase 2 therapy targeting adolescents with recent-onset type 1 diabetes mellitus. This program evolved from our second technology platform involving the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function to treat and ultimately eliminate autoimmune diseases.